A prospective eight-year follow-up found plasma pTau217 levels consistent with amyloid positivity are common in community-dwelling older adults but did not predict mortality or later decline in autonomy. The study adds uncertainty around the usefulness of pTau217 as a stand-alone prognostic biomarker for hard outcomes over long horizons.